Terms: = Brain cancer AND CDK4, PSK-J3, 1019, ENSG00000135446, MGC14458, CMM3, P11802
399 results:
1. Pembrolizumab response in stage IV luminal-type breast cancer with high microsatellite instability: a case report.
Inakami K; Fujita N; Iguchi C; Enomoto Y; Minohata J; Sata A; Miyagawa Y; Yanagisawa T; Saitoh T; Nomura T; Sawai Y; Takahara K; Kasugai T; Shiba E
J Med Case Rep; 2024 May; 18(1):214. PubMed ID: 38689362
[TBL] [Abstract] [Full Text] [Related]
2. DMC-siERCC2 hybrid nanoparticle enhances TRAIL sensitivity by inducing cell cycle arrest for glioblastoma treatment.
Song M; Wang T; Liu T; Lei T; Teng X; Peng Q; Zhu Q; Chen F; Zhao G; Li K; Qi L
Biomed Pharmacother; 2024 May; 174():116470. PubMed ID: 38565061
[TBL] [Abstract] [Full Text] [Related]
3. Glioblastoma Therapy: Past, Present and Future.
Obrador E; Moreno-Murciano P; Oriol-Caballo M; López-Blanch R; Pineda B; Gutiérrez-Arroyo JL; Loras A; Gonzalez-Bonet LG; Martinez-Cadenas C; Estrela JM; Marqués-Torrejón MÁ
Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38473776
[TBL] [Abstract] [Full Text] [Related]
4. Comparative transcriptomic analysis reveals differences in gene expression and regulatory pathways between nonacral and acral melanoma in Asian individuals.
Chiu YJ; Li CY; Wang TH; Ma H; Chou TY
J Dermatol; 2024 May; 51(5):659-670. PubMed ID: 38469735
[TBL] [Abstract] [Full Text] [Related]
5. Fulvestrant and everolimus efficacy after cdk4/6 inhibitor: a prospective study with circulating tumor DNA analysis.
Vasseur A; Cabel L; Hego C; Takka W; Trabelsi Grati O; Renouf B; Lerebours F; Loirat D; Brain E; Cottu P; Sablin MP; Pierga JY; Callens C; Renault S; Bidard FC
Oncogene; 2024 Apr; 43(16):1214-1222. PubMed ID: 38413796
[TBL] [Abstract] [Full Text] [Related]
6. Adult epithelioid glioblastoma exhibits an extremely poor prognosis and high frequency of SWI/SNF complex mutation: Insights from a retrospective study.
Xi S; Jiang S; Li H; Huang Q; Lu J; Zhang X; Li Z; Zeng J
Int J Cancer; 2024 Jul; 155(1):172-183. PubMed ID: 38411299
[TBL] [Abstract] [Full Text] [Related]
7. The development of a custom RNA-sequencing panel for the identification of predictive and diagnostic biomarkers in glioma.
Shirai Y; Ueno T; Kojima S; Ikeuchi H; Kitada R; Koyama T; Takahashi F; Takahashi K; Ichimura K; Yoshida A; Sugino H; Mano H; Narita Y; Takahashi M; Kohsaka S
J Neurooncol; 2024 Mar; 167(1):75-88. PubMed ID: 38363490
[TBL] [Abstract] [Full Text] [Related]
8. Molecular signature of stem-like glioma cells (SLGCs) from human glioblastoma and gliosarcoma.
Zechel C; Loy M; Wegner C; Dahlke E; Soetje B; Baehr L; Leppert J; Ostermaier JJ; Lueg T; Nielsen J; Elßner J; Willeke V; Marzahl S; Tronnier V; Madany Mamlouk A
PLoS One; 2024; 19(2):e0291368. PubMed ID: 38306361
[TBL] [Abstract] [Full Text] [Related]
9. Characterization of a Preclinical In Vitro Model Derived from a SMARCA4-Mutated Sinonasal Teratocarcinosarcoma.
Lorenzo-Guerra SL; Codina-Martínez H; Suárez-Fernández L; Cabal VN; García-Marín R; Riobello C; Vivanco B; Blanco-Lorenzo V; Sánchez-Fernández P; López F; Llorente JL; Hermsen MA
Cells; 2023 Dec; 13(1):. PubMed ID: 38201285
[TBL] [Abstract] [Full Text] [Related]
10. Genetic alterations that deregulate RB and PDGFRA signaling pathways drive tumor progression in IDH2-mutant astrocytoma.
Tateishi K; Miyake Y; Nakamura T; Iwashita H; Hayashi T; Oshima A; Honma H; Hayashi H; Sugino K; Kato M; Satomi K; Fujii S; Komori T; Yamamoto T; Cahill DP; Wakimoto H
Acta Neuropathol Commun; 2023 Nov; 11(1):186. PubMed ID: 38012788
[TBL] [Abstract] [Full Text] [Related]
11. Paclitaxel plus Eftilagimod Alpha, a Soluble LAG-3 Protein, in Metastatic, HR+ Breast cancer: Results from AIPAC, a Randomized, Placebo Controlled Phase IIb Trial.
Wildiers H; Armstrong A; Cuypere E; Dalenc F; Dirix L; Chan S; Marme F; Schröder CP; Huober J; Duhoux FP; Vuylsteke P; Jager A; Brain E; Kuemmel S; Pápai Z; Menke-van der Houven van Oordt CW; Perjesi L; Mueller C; Brignone C; Triebel F
Clin Cancer Res; 2024 Feb; 30(3):532-541. PubMed ID: 37939105
[TBL] [Abstract] [Full Text] [Related]
12. Adjunctive Medication Management and Contingency Management to enhance adherence to acamprosate for alcohol dependence: the ADAM trial RCT.
Donoghue K; Boniface S; Brobbin E; Byford S; Coleman R; Coulton S; Day E; Dhital R; Farid A; Hermann L; Jordan A; Kimergård A; Koutsou ML; Lingford-Hughes A; Marsden J; Neale J; O'Neill A; Phillips T; Shearer J; Sinclair J; Smith J; Strang J; Weinman J; Whittlesea C; Widyaratna K; Drummond C
Health Technol Assess; 2023 Oct; 27(22):1-88. PubMed ID: 37924307
[TBL] [Abstract] [Full Text] [Related]
13. Combination therapy of niclosamide with gemcitabine inhibited cell proliferation and apoptosis via Wnt/β-catenin/c-Myc signaling pathway by inducing β-catenin ubiquitination in pancreatic cancer.
Kang HW; Kim JH; Lee DE; Lee YS; Kim MJ; Kim HS; Fang S; Lee BE; Lee KJ; Yoo J; Kim HJ; Park JS
Cancer Biol Ther; 2023 Dec; 24(1):2272334. PubMed ID: 37917550
[TBL] [Abstract] [Full Text] [Related]
14. FLNA expression modulates pathological markers of pituitary neuroendocrine tumours.
Toledo J; Perez PA; Zanetti M; Díaz-Torga G; Mukdsi JH; Gutierrez S
J Endocrinol; 2024 Jan; 260(1):. PubMed ID: 37855268
[TBL] [Abstract] [Full Text] [Related]
15. Current treatment landscape of HR+/HER2- advanced breast cancer in the Nordics: a modified Delphi study.
Geisler J; Karihtala P; Tuxen M; Valachis A; ; Holm B
Acta Oncol; 2023 Dec; 62(12):1680-1688. PubMed ID: 37713138
[TBL] [Abstract] [Full Text] [Related]
16. Personalized Biomarker-Based Umbrella Trial for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: KCSG HN 15-16 TRIUMPH Trial.
Keam B; Hong MH; Shin SH; Heo SG; Kim JE; Ahn HK; Lee YG; Park KU; Yun T; Lee KW; Kim SB; Lee SC; Kim MK; Cho SH; Oh SY; Park SG; Hwang S; Nam BH; Kim S; Kim HR; Yun HJ;
J Clin Oncol; 2024 Feb; 42(5):507-517. PubMed ID: 37699162
[TBL] [Abstract] [Full Text] [Related]
17. KDM2B-Rearranged Soft Tissue Sarcomas Expand the Concept of BCOR-Associated Sarcoma.
Motoi T; Hirata M; Kukita Y; Satomi K; Tamura H; Adachi S; Matsushita Y; Horiguchi SI; Hishima T; Ikegami M; Okuma T; Tao K; Arakawa A; Ogawa C; Matsuda K; Ichimura K; Nakamura H; Mori T; Yoshida A
Mod Pathol; 2023 Nov; 36(11):100317. PubMed ID: 37634866
[TBL] [Abstract] [Full Text] [Related]
18. cdk4/6 Inhibition Sensitizes Intracranial Tumors to PD-1 Blockade in Preclinical Models of brain Metastasis.
Nayyar N; de Sauvage MA; Chuprin J; Sullivan EM; Singh M; Torrini C; Zhang BS; Bandyopadhyay S; Daniels KA; Alvarez-Breckenridge C; Dahal A; Brehm MA; Brastianos PK
Clin Cancer Res; 2024 Jan; 30(2):420-435. PubMed ID: 37611074
[TBL] [Abstract] [Full Text] [Related]
19. ROS1 Alterations as a Potential Driver of Gliomas in Infant, Pediatric, and Adult Patients.
Meredith DM; Cooley LD; Dubuc A; Morrissette J; Sussman RT; Nasrallah MP; Rathbun P; Yap KL; Wadhwani N; Bao L; Wolff DJ; Ida C; Sukhanova M; Horbinski C; Jennings LJ; Farooqi M; Gener M; Ginn K; Kam KL; Sasaki K; Kanagal-Shamanna R; Alexandrescu S; Brat D; Lu X
Mod Pathol; 2023 Nov; 36(11):100294. PubMed ID: 37532182
[TBL] [Abstract] [Full Text] [Related]
20. A comprehensive genomic study of 390 H3F3A-mutant pediatric and adult diffuse high-grade gliomas, CNS WHO grade 4.
Williams EA; Brastianos PK; Wakimoto H; Zolal A; Filbin MG; Cahill DP; Santagata S; Juratli TA
Acta Neuropathol; 2023 Sep; 146(3):515-525. PubMed ID: 37524847
[TBL] [Abstract] [Full Text] [Related]
[Next]
